Validation of techniques for the prediction of carboplatin exposure:: Application of Bayesian methods

被引:36
作者
Huitema, ADR
Mathôt, RAA
Tibben, MM
Schellens, JHM
Rodenhuis, S
Beijnen, JH
机构
[1] Slotervaart Hosp, Netherlands Canc Inst, Dept Pharm & Pharmacol, NL-1066 EC Amsterdam, Netherlands
[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[3] Univ Utrecht, Fac Pharm, Dept Drug Toxicol, Utrecht, Netherlands
关键词
D O I
10.1067/mcp.2000.106827
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Several methods have been developed for the prediction of carboplatin exposure to facilitate pharmacokinetic guided dosing. The aim of this study was to develop and validate sparse data Bayesian methods for the estimation of carboplatin exposure and to validate other commonly applied techniques, such as the Chatelut formula, the Sorensen limited sampling model, and the Calvert formula, in which glomerular filtration rate was estimated with the Cockcroft-Gault, the Jelliffe, and the recently proposed Wright formulas, Methods: Complete concentration-time curves were available for a total of 43 patients (45 courses) receiving carboplatin (265 or 400 mg/m(2)/day) in a 1-hour infusion for 4 consecutive days in combination with thiotepa and cyclophosphamide, A population two-compartment model was developed on an index set of 12 courses. The other 33 courses served as validation set. Bayesian estimates were generated with the population parameters by use of either one or two randomly timed samples or two samples at optimal time points determined with the D-optimality theory. Results: The Bayesian methods provided an accurate and precise prediction of the area under the concentration-time curve (bias <4% and precision less than or equal to 18%). The other formulas (Sorensen model, Chatelut, and Calvert with Jelliffe, Cockcroft-Gault, and Wright) resulted in a precision >18%, whereas the Jelliffe formula and the Sorensen model resulted in a bias >12%. Conclusion: The applicability of a Bayesian method for the prediction of the carboplatin exposure by use of one or two samples without the necessity for exact timing of infusion duration and sampling was demonstrated. The Bayesian method may be very instrumental to execute pharmacokinetic guided dosing for carboplatin.
引用
收藏
页码:621 / 630
页数:10
相关论文
共 39 条
[1]   Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing [J].
Ando, Y ;
Minami, H ;
Saka, H ;
Ando, M ;
Sakai, S ;
Shimokata, K .
BRITISH JOURNAL OF CANCER, 1997, 76 (08) :1067-1071
[2]   Estimation of the area under the concentration-versus-time curve of carboplatin following irinotecan using a limited sampling model [J].
Asai, G ;
Ando, Y ;
Saka, H ;
Ando, M ;
Sugiura, S ;
Sakai, S ;
Hasegawa, Y ;
Shimokata, K .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (9-10) :725-727
[3]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[4]   PREDICTION OF CARBOPLATIN CLEARANCE FROM STANDARD MORPHOLOGICAL AND BIOLOGICAL PATIENT CHARACTERISTICS [J].
CHATELUT, E ;
CANAL, P ;
BRUNNER, V ;
CHEVREAU, C ;
PUJOL, A ;
BONEU, A ;
ROCHE, H ;
HOUIN, G ;
BUGAT, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (08) :573-580
[5]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[6]  
D'Argenio DZ, 1997, ADAPT 2 USERS GUIDE
[7]   OPTIMAL SAMPLING TIMES FOR PHARMACOKINETIC EXPERIMENTS [J].
DARGENIO, DZ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1981, 9 (06) :739-756
[8]   Application of the area under the curve of carboplatin in predicting toxicity and efficacy [J].
de Lemos, ML .
CANCER TREATMENT REVIEWS, 1998, 24 (06) :407-414
[9]   A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children [J].
Doz, F ;
Urien, S ;
Chatelut, E ;
Michon, J ;
Rubie, H ;
Zucker, JM ;
Canal, P ;
Bastian, G .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (03) :250-254
[10]   Clinical pharmacokinetics and dose optimisation of carboplatin [J].
Duffull, SB ;
Robinson, BA .
CLINICAL PHARMACOKINETICS, 1997, 33 (03) :161-183